Therapeutics for Women's Health: Technologies and Global Markets

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• What's New in this Update?
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Methodology
• Geographic Breakdown
• Analyst's Credentials

Chapter 2 Summary and Highlights

Chapter 3 Overview of Technologies and Global Markets

• Disease Overview and Definitions
• Historical Background
• Market Driving Factors and Opportunities
• Aging Female Population
• Government Involvement and Increased Funding
• Increasing Awareness Regarding Women's Disorders and Treatments
• Market Restraints
• Poor Diagnosis
• Availability of Alternate Treatment Options and Lifestyle Changes
• Unavailability of Novel Treatments
• High Treatment Cost of Osteoporosis
• Opportunities
• Rising Female Population in Asia-Pacific
• Increased Demand for Technology Innovation
• Mergers and Acquisitions

Chapter 4 Impact of COVID-19 Pandemic

• Implications on Women's Health and Diagnosis
• Implications on Cancer Treatment
• Impact on Oncology Pharmaceuticals Market

Chapter 5 Pipeline Assessment and Analysis

• Women's Health Therapeutics: Key Clinical Trial Developments
• List of Drugs in Pipeline
• Overview of Osteoporosis Drug Development Pipeline
• Late-stage Pipeline Drugs

Chapter 6 Regulatory Structure

• Overview of Regulations
• U.S.
• Canada
• Europe
• Japan

Chapter 7 Market Breakdown by Women’s Health Disorder

• Introduction
• Menopause-Related Diseases
  • Overview
  • Symptoms
  • Risk Factors
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecast
  
  
• Postmenopausal Osteoporosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  
  
• Endometriosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  
  
• Polycystic Ovary Syndrome
  • Overview
  • Etiology
  • Reducing PCOS Risk
  • Epidemiology and Economic Burden
  • Disease Symptoms and Risk Factors
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  
  
• Breast Cancer
  • Overview
  • Market Size and Forecasts
  
  

Chapter 8 Market Breakdown by Region

• Introduction
• North America
• U.S.
• Canada
• Mexico
• Europe
• U.K.
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Rest of Asia-Pacific
• Rest of the World
• South America
• Middle East and Africa

Chapter 9 Pricing and Reimbursement

• Overview of Pricing and Reimbursement
• U.S.
• Canada
• Europe
• Japan

Chapter 10 Competitive Landscape and Key Developments

• Market Players and Strategies
• Blockbuster Breast Cancer Pharmaceutical Brands
• Patent Analysis
• List of Key Patents
• Key Developments
• Mergers and Acquisitions
• Development of Innovative Products/Novel Product Launch
• Agreements, Collaborations and Partnerships
• Key Products

Chapter 11 Company Profiles

• Abbvie Inc.
• Amgen Inc.
• Asahi Kasei
• Astrazeneca plc
• Bayer AG
• Bristol-Myers Squibb
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Eisai
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Merck Kgaa
• Novartis AG
• Novo Nordisk
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.

Chapter 12 Conclusions: Outlook for Women’s Health Therapeutics

• Major Developments to Influence Market
• Therapeutic Developments
• Demographic and Economic Trends
• Income Growth in Emerging Markets
• Future Outlook

Chapter 13 Appendix A: Glossary of Terms

Chapter 14 Appendix B: Industry and Professional Organizations

Chapter 15 Appendix C: Acronyms Used in This Report

• Acronyms Used in This Report

List of Tables

Summary Table A : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Summary Table B : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)
Table 2 : Recent M&A Deals in the Global Market for Women’s Health Therapeutics, 2019-2021
Table 3 : Novel Breast Cancer Drug Approvals
Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development
Table 5 : Pipeline Molecules, Endometriosis
Table 6 : Pipeline Molecules, Uterine Fibroids
Table 7 : Pipeline Molecules, All Other Indications
Table 8 : Pipeline Molecules, Osteoporosis
Table 9 : Elagolix Snapshot
Table 10 : Vilaprisan Snapshot
Table 11 : Evenity Snapshot
Table 12 : Relugolix Snapshot
Table 13 : Proellex Snapshot
Table 14 : Esmya Snapshot
Table 15 : TX-004HR Snapshot
Table 16 : TX-001HR Snapshot
Table 17 : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Table 18 : FDA Approved Estrogen-only Medicines
Table 19 : FDA Approved Progestin-Only Medicines
Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines
Table 21 : FDA Approved Combination Estrogen and Hormone Medicines
Table 22 : Vagifem (10mcg), Patent Expiration
Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026
Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration
Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026
Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026
Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026
Table 29 : TNM Classifications of Breast Cancers
Table 30 : Global Breast Cancer Incidence, 2016-2021
Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018
Table 32 : Types of Hormone Therapy for Breast Cancer
Table 33 : Drugs Commonly Used to Treat Breast Cancer
Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026
Table 35 : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 36 : North American Market for Women’s Health Therapeutics, by Country, Through 2026
Table 37 : North American Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 38 : U.S. Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 39 : Canadian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 40 : Mexican Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 41 : European Market for Women’s Health Therapeutics, by Country, Through 2026
Table 42 : European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 43 : U.K. Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 44 : German Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 45 : French Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 46 : Spanish Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 47 : Italian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 48 : Rest of the European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 49 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 50 : RoW Market for Women’s Health Therapeutics, by Sub-region Through 2026
Table 51 : RoW Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 52 : South American Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 53 : Middle East and African Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020
Table 55 : Major Women’s Health Therapeutics Pharmaceuticals by Company Revenue, 2020
Table 56 : Global Market Shares of Women’s Health Therapeutics, by Company Revenue, 2020
Table 57 : Patent Review, 2021
Table 58 : Novel Women’s Health Therapeutic Drug Approvals, 2021
Table 59 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development
Table 60 : Marketed Products, Postmenopausal Osteoporosis
Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 62 : AbbVie Inc.: Net Revenue, 2017-2020
Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio
Table 64 : AbbVie Inc.: Marketed Products
Table 65 : AbbVie Inc.: Key Developments, 2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Allergan plc: Net Revenue, 2017-2019
Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio
Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020
Table 70 : Amgen: Financials, 2014-2020
Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio
Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 73 : Bayer AG: Marketed Products
Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio
Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 76 : Bayer AG: Net Revenue, 2018-2020
Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio
Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products
Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020
Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products
Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020
Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio
Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 85 : Roche: Oncology Pharmaceutical Product Portfolio
Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
Table 92 : Merck & Co. Inc.: Marketed Products
Table 93 : Merck & Co. Inc.: Net Revenue, 2017-2019
Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 96 : Merck KGaA Marketed Products
Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio
Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 99 : Novo Nordisk: Marketed Products
Table 100 : Novo Nordisk: Net Revenue, 2017-2019
Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
Table 102 : Pfizer Inc.: Women’s Health-Marketed Products, by Indication
Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 104 : Pfizer Inc. Net Revenue, 2017-2019
Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio
Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
Table 109 : New Cancer Cases in the U.S., by Age Group, 2018
Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
Table 111 : Glossary of Terms Used in Women’s Health Therapeutics
Table 112 : Acronyms Used in Women’s Health Therapeutics

List of Figures

Summary Figure A : Global Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Summary Figure B : Global Market for Women’s Health Therapeutics, by Region, 2020-2026
Figure 1 : Distribution of Global Elderly Population, by Age Group and Sex, 2020
Figure 2 : Distribution of Global Elderly Population, by Age Group and Sex, 2050
Figure 3 : Funding for Research in Women’s Health, by Disease Condition/Category, 2014-2016
Figure 4 : Funding for Research in Women’s Health, 2014-2016
Figure 5 : Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014
Figure 6 : Global Market for Women’s Health Therapeutics, 2018-2026
Figure 7 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 8 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2026
Figure 9 : Global Market for Menopause Therapeutics, 2020-2026
Figure 10 : Global Market for Menopause Therapeutics, by Region, 2020-2026
Figure 11 : Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016
Figure 12 : Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026
Figure 13 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020-2026
Figure 14 : Global Market for Endometriosis Therapeutics, 2018-2026
Figure 15 : Global Market for Endometriosis Therapeutics, by Region, 2020-2026
Figure 16 : Global Market for PCOS Therapeutics, 2018-2026
Figure 17 : Global Market for PCOS Therapeutics, by Region, 2018-2026
Figure 18 : Global Market for Breast Cancer Therapeutics, 2018-2026
Figure 19 : Global Market for Breast Cancer Therapeutics, by Region, 2020-2026
Figure 20 : Global Market for Women’s Health Therapeutics, by Region, 20202026
Figure 21 : North American Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 22 : North American Market for Women’s Health Therapeutics, 2018-2026
Figure 23 : North American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 24 : North American Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 25 : U.S. Market for Women’s Health Therapeutics, 2018-2026
Figure 26 : Canadian Market for Women’s Health Therapeutics, 2018-2026
Figure 27 : Mexican Market for Women’s Health Therapeutics, 2018-2026
Figure 28 : European Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 29 : European Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 30 : European Market for Women’s Health Therapeutics, 2018-2026
Figure 31 : European Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 32 : U.K. Market for Women’s Health Therapeutics, 2018-2026
Figure 33 : German Market for Women’s Health Therapeutics, 2018-2026
Figure 34 : French Market for Women’s Health Therapeutics, 2018-2026
Figure 35 : Spanish Market for Women’s Health Therapeutics, 2018-2026
Figure 36 : Italian Market for Women’s Health Therapeutics, 2018-2026
Figure 37 : Rest of the European Market for Women’s Health Therapeutics, 2018-2026
Figure 38 : Asia-Pacific Market for Women’s Health Therapeutics, 2018-2026
Figure 39 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 40 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 41 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Figure 42 : Chinese Market for Women’s Health Therapeutics, 2018-2026
Figure 43 : Japanese Market for Women’s Health Therapeutics, 2018-2026
Figure 44 : Indian Market for Women’s Health Therapeutics, 2018-2026
Figure 45 : South Korean Market for Women’s Health Therapeutics, 2018-2026
Figure 46 : Rest of Asia-Pacific Countries’ Market for Women’s Health Therapeutics, 2018-2026
Figure 47 : RoW Market for Women’s Health Therapeutics, by Sub-region, 2018-2026
Figure 48 : RoW Market Shares of Women’s Health Therapeutics, by Subregion, 2020
Figure 49 : RoW Market for Women’s Health Therapeutics, 2018-2026
Figure 50 : RoW Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 51 : South American Market for Women’s Health Therapeutics, 2018-2026
Figure 52 : South American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 53 : Middle East and African Market for Women’s Health Therapeutics, 2018-2026
Figure 54 : Global Market Shares of Women’s Health Therapeutics, by Company, 2020
Figure 55 : AbbVie: Hematologic Oncology Annual Revenue, 2018-2020
Figure 56 : AbbVie Inc.: Revenue Share, by Country, 2020
Figure 57 : Allergan plc: Revenue Share, by Business Segment, 2017
Figure 58 : Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 59 : AstraZeneca’s Oncology Segment: Annual Revenue, 2018-2020
Figure 60 : Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 61 : Bayer AG: Revenue Share, by Region, 2018
Figure 62 : Bayer AG: Revenue Share, by Business Segment, 2018
Figure 63 : Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 64 : Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014-2016
Figure 65 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 66 : Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 67 : Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
Figure 68 : Roche: Oncology Annual Revenue, 2018-2020
Figure 69 : Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 70 : Johnson & Johnson’s Oncology Segment: Annual Revenue, 2018-2020
Figure 71 : Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018
Figure 72 : Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018
Figure 73 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 74 : Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 75 : Merck & Co.’s Oncology Pharmaceutical: Annual Revenue, 2018-2020
Figure 76 : Novartis’s Oncology Segment: Annual Revenue, 2018-2020
Figure 77 : Novo Nordisk: Revenue Share, by Region, 2018
Figure 78 : Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 79 : Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020
Figure 80 : Pfizer Inc.: Revenue Share, by Region, 2018
Figure 81 : Pfizer Inc.: Revenue Share, by Business Segment, 2018
Figure 82 : Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020
Figure 83 : Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021
Figure 84 : Rate of New Cancer Cases in the U.S., by Age Group, 2018

Companies Mentioned

• Abbvie Inc.
• Amgen Inc.
• Asahi Kasei
• Astrazeneca plc
• Bayer AG
• Bristol-Myers Squibb
• Daiichi Sankyo Co. Ltd.
• Eisai
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Merck Kgaa
• Novartis AG
• Novo Nordisk
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.